Theratechnologies (TSE:TH) has released an update.
Theratechnologies Inc., a biopharmaceutical company, has reported a robust second quarter in 2024 with a 25% increase in revenue to $22 million, and a significant milestone of $1 million in net income, indicating a profitable turn for the company. They also confirmed their 2024 full-year revenue guidance of $87 to $90 million with an Adjusted EBITDA of $13 to $15 million, showcasing sustained financial growth and operational success.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
